Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605942 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
A Phase 1 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01605942 is a Phase 1 study that was terminated before completion, run by Allergan. The registered enrollment target is 8 participants.
The verdict
NCT01605942, a Phase 1 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
Interventions
- DRUG Dexamethasone Drug Delivery System
- DRUG Placebo Drug Delivery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01605942
The ClinicalTrials.gov registry entry for NCT01605942 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone Drug Delivery System is the first listed.
NCT01605942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01605942 about?
NCT01605942 is a clinical study titled "A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery". This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
What is the current status of trial NCT01605942?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2012-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01605942?
The interventions under investigation include: Dexamethasone Drug Delivery System (DRUG), Placebo Drug Delivery System (DRUG).
Who is sponsoring clinical trial NCT01605942?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.